塞力医疗(603716)今日涨停，全天换手率30.03%，成交额6.70亿元，振幅9.73%。龙虎榜数据显示，营 业部席位合计净买入1981.66万元。 上交所公开信息显示，当日该股因日涨幅偏离值达10.98%、日换手率达30.03%上榜，营业部席位合计 净买入1981.66万元。 资金流向方面，今日该股主力资金净流入1.26亿元，其中，特大单净流入1.02亿元，大单资金净流入 2324.96万元。近5日主力资金净流入1.13亿元。 4月29日公司发布的一季报数据显示，一季度公司共实现营业收入2.87亿元，同比下降40.75%，实现净 利润-1432.09万元。（数据宝） 塞力医疗5月23日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 国泰海通证券股份有限公司总部 | 1737.01 | | | 买二 | 开源证券股份有限公司西安太华路证券营业部 | 1564.26 | | | 买三 | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券 营业部 | 1142.87 | ...

Group 1 - The cell immunotherapy concept index rose by 1.35%, ranking third among concept sectors, with 35 stocks increasing in value, including Seer Medical which hit the daily limit, and Sunshine Nuohuo, Shutai Shen, and Betta Pharmaceuticals showing significant gains of 12.55%, 11.77%, and 8.35% respectively [1] - The concept sector saw a net inflow of 246 million yuan, with 29 stocks receiving net inflows, and 5 stocks attracting over 50 million yuan in net inflows, led by Huahai Pharmaceutical with a net inflow of 143 million yuan [1] - The top stocks by net inflow included Seer Medical, Huadong Medicine, and Saifutian, with net inflows of 126 million yuan, 106 million yuan, and 74 million yuan respectively [1] Group 2 - The leading stocks by net inflow ratio were Saifutian, Seer Medical, and Hai Xin Co., with net inflow ratios of 20.66%, 18.75%, and 15.23% respectively [2] - Huahai Pharmaceutical had a daily increase of 7.45% with a turnover rate of 7.28%, while Seer Medical increased by 10.04% with a turnover rate of 30.03% [2] - Other notable stocks included Betta Pharmaceuticals with an 8.35% increase and a turnover rate of 5.70%, and Rongchang Bio with a 2.08% increase and a turnover rate of 4.97% [2] Group 3 - Stocks with significant declines included Yaoji Technology, Hainan Hai Pharmaceutical, and Nearshore Protein, which fell by 4.24%, 3.62%, and 3.19% respectively [1] - The overall performance of the cell immunotherapy sector reflects a positive trend, with a majority of stocks experiencing gains, indicating investor confidence in this area [1][2] - The data suggests a strong interest from institutional investors in the cell immunotherapy sector, as evidenced by the substantial net inflows into key stocks [1][2]

2025 年 1 月 23 日，公司披露了《关于持股 5%以上股东减持股份计划公告》 （公告编号：2025-009），上海盎泽计划在公告披露日起 15 个交易日后的三个月， 通过集中竞价和大宗交易方式分别减持不超过所持公司股份 1,909,882 股和 3,819,765 股，减持合计不超过公司总股本的 3%。 2025 年 5 月 23 日，公司收到上海盎泽发来的《股份减持情况告知函》，截 至本公告披露日，上海盎泽在 2025 年 2 月 24 日通过集中竞价交易方式累计减持 本公司股份 1,899,601 股，占公司截至 2025 年 5 月 20 日总股本的 0.99%。 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 持股 5%以上股东的 ...

Core Viewpoint - The pharmaceutical sector in China is experiencing significant growth, driven by favorable government policies and increasing international market share, with a notable rise in innovative drug development and exports [1][2]. Group 1: Market Performance - On May 23, 2025, pharmaceutical stocks collectively surged, with sectors like Helicobacter pylori, AI healthcare concepts, and weight-loss drugs rising over 2% [1]. - Hai Chen Pharmaceutical's stock hit a 20% limit up within three minutes of opening, reaching a new high in two and a half years [1]. - Heng Rui Pharmaceutical officially listed on the Hong Kong stock market, with its stock price increasing by approximately 30% post-opening, raising about 9.9 billion HKD through an IPO of 224.5 million shares, marking the largest IPO in the Hong Kong pharmaceutical sector in five years [1]. Group 2: Export and Innovation - In Q1 2025, China's pharmaceutical and healthcare product exports reached 26.632 billion USD, a year-on-year increase of 4.39%, while imports decreased by 4.42% to 20.456 billion USD, indicating a domestic industry upgrade and import substitution effect [1][2]. - The United States remains the largest single market for Chinese pharmaceutical exports, with exports amounting to 4.639 billion USD, a 9.6% increase, primarily driven by raw materials and disposable medical supplies [2]. - By the end of 2024, the number of active innovative drugs developed by Chinese companies reached 3,575, ranking first globally, with domestic products accounting for 42% of newly approved innovative drugs, up from less than 10% in 2015 [2]. Group 3: Future Outlook - Analysts predict that 2025 will be a pivotal year for the pharmaceutical industry in China, marking the beginning of significant revenue growth, profitability for many companies, and an extended valuation cycle due to improvements in payment systems [2].

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-042 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 30 日（星期五）10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 5 月 23 日（星期五）至 5 月 29 日（星期四）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （ir@thalys.net.cn）进行提问。公司将在说明会上对投资者普遍关注的问题进 行 ...

Group 1 - The company has established a special account for the storage of raised funds and signed a four-party supervision agreement to ensure compliance with regulations and protect investors' rights [1][2] - The total amount raised from the issuance of convertible bonds is RMB 543.31 million, with a net amount of RMB 532.698 million after deducting related expenses [1] - The special account is designated solely for the storage and use of funds related to the medical consumables centralized operation service (SPD) project [3][4] Group 2 - The four-party supervision agreement involves the company, its subsidiaries, the underwriting institution, and the bank, ensuring proper management of the raised funds [2][3] - The agreement stipulates that any funds stored in the account must not be used for purposes other than the specified project [3] - The underwriting institution is responsible for ongoing supervision and can conduct site investigations and inquiries regarding the use of the funds [3][4]

证券代码：603716 证券简称：塞力医疗 公告编号：2025-040 塞力斯医疗科技集团股份有限公司 (一)非累积投票议案 审议结果：通过 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 19 日 (二)股东大会召开的地点：公司（武汉市东西湖金山大道 1310 号）A 栋 A 会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 份总数的比例（%） 17.7070 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由塞力斯医疗科技集团股份有限公司董事会召集，由公司董事 长温伟先生主持。所有表决方式均符合《公司法》及《公司章程》的相关规定。 (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 ? 报备文件 经与会董事和记录人签字确认并加盖董事会印章的股东大会决议 表决情况： | 股东类型 | | 同意 | | 反对 | | 弃权 | | ...

| | | 塞力斯医疗科技集团股份有限公司 关于控股子、孙公司开立募集资金专用账户并签署 募集资金专户存储四方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会核发的《关于核准塞力斯医疗科技股份有限公司 公开发行可转换公司债券的批复》（证监许可[2020]1033 号）核准，塞力斯医 疗科技集团股份有限公司（原名称为塞力斯医疗科技股份有限公司，以下简称"公 司"）于 2020 年 8 月 21 日公开发行面值总额 54,331 万元可转换公司债券，募 集资金总额为人民币 543,310,000.00 元，扣除承销保荐费用及与本次可转换公 司债券发行直接相关的其他发行费用（不含增值税）后的募集资金净额为人民币 533,298,679.25 元。上述资金已于 2020 年 8 月 27 日全部到位，并经中审众环 会计师事务所（特殊普通合伙）于 2020 年 8 月 27 日出具的众环验字（2020）010054 号验资报告审验，扣除承销保荐费用及与本次可转换公司债券发行直 ...

证券代码：603716 证券简称：塞力医疗 公告编号：2025-040 塞力斯医疗科技集团股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 19 日 (二)股东大会召开的地点：公司（武汉市东西湖金山大道 1310 号）A 栋 A 会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 349 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 33,119,049 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 17.7070 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由塞力斯医疗科技集团股份有限公司董事会召集，由公司董事 长温伟先生主持。所有表决方式均符合《公司法》及《公司章 ...

Group 1 - The DRG/DIP concept declined by 3.30%, ranking among the top declines in the concept sector, with notable declines in companies such as Chuangying Huikang, ST Yilianzhong, and Jiahe Meikang [1][2] - The DRG/DIP concept experienced a net outflow of 4.92 billion yuan in main funds, with 19 stocks seeing net outflows, and 13 stocks with outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Donghua Software, with a net outflow of 1.26 billion yuan, followed by Chuangying Huikang, Weining Health, and Dian Diagnosis [2][3] Group 2 - The top stocks with net outflows in the DRG/DIP concept included Donghua Software (-3.97%), Chuangying Huikang (-6.76%), and Weining Health (-4.60%) [2][3] - Conversely, the stocks with net inflows included Huaping Co., Guoke Hengtai, and Wanda Information, with net inflows of 238.84 million yuan, 166.15 million yuan, and 121.00 million yuan respectively [2]